Puma Biotechnology Third Quarter 2026 Results Call - PUMA BIOTECHNOLOGY INC

Explicit Guidance:

• FY2026 Net Product Revenue (Neuralynx): Revised range of $205–$208 million (previously $105–$209 million).
• FY2026 Royalty Revenue: $18–$19 million (previously $20–$23 million), reflecting reduced royalty rates in China due to generic market share thresholds.
• FY2026 Net Income: $20–$22 million (previously $17–$20 million), excluding potential tax valuation allowance releases.
• FY2026 Gross-to-Net Adjustments: 27.5%–28.0% (higher than prior guidance), driven by increased Medicaid share.
• FY2026 Operating Expenses: Total expenses anticipated to be higher than 2025; SG&A expected to remain flat; R&D expected to increase 28–30% YoY due to clinical trial progress.
• Q4 2026 Net Product Revenue (Neuralynx): $56–$58 million.
• Q4 2026 Royalty Revenue: $11–$12 million.
• Q4 2026 Net Income: $10–$12 million.
• Q4 2026 Gross-to-Net Adjustments: 28%–29%.
• No license/royalty revenue expected in 2026.
• Cost of Sales: Amortization of milestones will continue at approx. $2.4 million per quarter through the end of the license term.

Business-Segment Outlook:

• Neuralynx (Breast Cancer): Management anticipates 2026 will mark the second consecutive year-over-year demand increase for Neuralynx in the U.S., a historic first for the product's launch. Commercial strategy focuses on expanding prescriber base for HER2-positive early-stage and metastatic settings, with continued emphasis on dose escalation (currently 80% of starts at reduced dose) to improve adherence and reduce recurrence risk.
• International Expansion: Recent expansion noted with the Q1 2026 launch of Neuralynx in Thailand (extended adjuvant setting); continued support expected for global partners.
• Pipeline (Aliceridib/Alisca):
  • ALISCA Breast 1 (HER2-negative HR+ breast cancer): Interim data expected at San Antonio Breast Cancer Symposium (Dec 2026); trial enrollment amended to 40mg and 50mg doses only. Management believes current data supports proceeding to Phase 3; regulatory engagement on Phase 3 design anticipated in H1 2027.
  • ALISCA Lung 1 (SCLC monotherapy): Dose escalated to 70mg BID; additional interim data expected in 2027.
  • ALISCA Lung 2 (SCLC combo with paclitaxel): Initiated; initial data anticipated in 2027.
• Licensing/M&A: Company actively evaluating commercial and development-stage assets for potential in-licensing or acquisition to diversify portfolio and leverage existing R&D/commercial infrastructure; no updates on specific targets at this time.

Market and Competitive Outlook:

• Channel Dynamics: Shift toward Specialty Distributor (SD) channel continuing (61% of Q3 business vs. 39% Specialty Pharmacy); growth driven by GPOs and 340B purchasing.
• Pricing/Reimbursement: Higher Medicaid share driving increased gross-to-net adjustments.
• Competitive Pressure: China royalty rate reduced effective immediately following Q3 2026 reporting of generic market share reaching specific thresholds; royalty revenue for 2026 revised downward.
• Demand Trends: Q3 U.S. demand saw 3% QoQ decrease but 5% YoY increase; however, new patient starts declined 13% QoQ and 9% YoY, indicating a need for continued prescriber education.

Macro / Industry Outlook:

• Regulatory/Tariffs: Management believes current or proposed U.S. tariffs will not have a material impact on product costs or results of operations (manufacturing costs represent mid-to-high single-digit % of COGS), though acknowledges trade policy remains unpredictable.
• Tax: Deferred tax asset valuation allowance review ongoing; no determination made yet on timing or size of potential adjustments, which could impact net income.

Strategic Initiatives:

• Clinical Trial Amendments: ALISCA Breast 1 amended to exclude 30mg dose group to focus on higher efficacy signals; ALISCA Lung 1 dose increased from 50mg to 70mg BID.
• Financial Discipline: Commitment to maintaining positive net income in 2026; readiness to reduce SG&A/R&D expenses if needed to achieve guidance.
• Debt Status: Company is now debt-free following final loan payment in Q2 2026; $108.5 million in cash/securities held as of Sept 30, 2026.

Risks and Headwinds to Outlook:

• Clinical Uncertainty: Future regulatory decisions on Phase 3 design (Breast) or trial outcomes (Lung) could alter the development timeline and capital requirements.
• Sales Volatility: Q3 showed QoQ decreases in prescriptions (-5%) and new patient starts (-13%), despite overall demand growth; temporary sales force vacancies caused call activity decline.
• Royalty Reduction: Structural reduction in royalty revenue from China due to generic competition thresholds.
• Regulatory/Trade Policy: Unpredictable shifts in U.S. and international trade policies could eventually impact manufacturing costs.
• Tax Uncertainty: Potential realization of tax valuation allowance could significantly alter full-year net income.

Management Tone on the Future:

• Cautiously Optimistic: Confident in the "demand-driven growth" trend, citing the first consecutive YoY demand increases in the product's history.
• Disciplined: Emphasis on "financial responsibility" and "positive net income" as primary objectives; willing to cut costs to meet targets.
• Forward-Looking Confidence: Belief that updated Breast 1 data will be "supportive" of Phase 3; expectation that sales force normalization will stabilize activity metrics.
• Hedges: Avoided definitive language on Phase 3 success, noting only that data is "supportive" of proceeding; explicitly excluded tax asset releases from income guidance.

Miscellaneous:

• Inventory: Q3 2026 saw an inventory drawdown of approx. $1.5 million (vs. $1 million in Q2); network maintained approx. 2 weeks of inventory.
• Financial Metrics: Q3 Net Income (GAAP) $6M ($0.11/share); Q3 Net Income (Non-GAAP) $8M ($0.15/share). Cash earned in Q3: $14.7M.
• Date Context: Transcript reflects a Q3 2026 earnings call dated November 5, 2026.